Screening for hepatitis B virus and tuberculosis infection in patients with moderate‐to‐severe psoriasis recruiting for biologic therapy in China

Abstract

Biologics have greatly advanced the therapy of moderate‐to‐severe psoriasis. Screening for Hepatitis B virus (HBV) and tuberculosis (TB) infection is mandatory before biologic therapy to avoid the risk of active infection, which is more likely to be disseminated, fulminant and fatal. Testing and treatment for latent TB infection (LTBI) in at‐risk populations is strongly recommended by recent WHO's guidelines.¹ Both HBV and TB infection are endemic in China and also represent important issues for global public health. The purpose of this study was to describe the screening results of HBV and TB infection in patients with moderate‐to‐severe psoriasis in China, which has not been reported.

This article is protected by copyright. All rights reserved.

http://bit.ly/2CTHyCR